Viewing nowCombinationPamika Tablet 5/40 mg
Olmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Pharma Co., Ltd.

MFDS item code 201405514 · Approved 2014.11.25 · Insurance code 653005510
Treatment of essential hypertension not controlled by monotherapy
This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled with monotherapy of amlodipine or olmesartan medoxomil. It helps effectively lower blood pressure and prevent cardiovascular complications, making it a good choice for hypertension treatment.
Administer 1 tablet of this medicine once daily with water, with or without food. It is recommended to take it at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood-pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. This medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine must not be administered to patients with severe hepatic impairment. (See section 2, Patients who must not be administered this medicine, under Precautions for Use.) ∘ Older adults: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.
∘ Children: The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established.
This medication can cause serious harm or death to the fetus and newborn, especially during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used in patients with known allergies to active ingredients or related components, those who are pregnant or breastfeeding, patients with severe liver disease or aortic stenosis, patients with biliary obstruction, those undergoing kidney dialysis, patients in a state of shock, and specific diabetes patients. Patients who are depleted of fluids or salt may experience hypotension, so careful monitoring should be conducted during initial administration, and appropriate actions should be taken if blood pressure drops too low. Caution should also be exercised when administering to patients with rapidly dilating blood vessels, severe heart disease, congestive heart failure, or weakened kidney function and liver impairment. During treatment, side effects such as dizziness, headache, hypotension, orthostatic hypotension, dry mouth, rash, edema, and fatigue may occur, and if any adverse symptoms arise, medical consultation is necessary. This medication may interact with other antihypertensives, diuretics, antibiotics, grapefruit juice, etc., so it is essential to inform about other medications or foods being taken, especially avoiding grapefruit juice. This medication should not be taken during pregnancy, and women planning to become pregnant or who are pregnant should consult healthcare providers. Breastfeeding mothers should consult with their doctor regarding whether to continue breastfeeding or discontinue medication, as this medication can pass into breast milk. It is not recommended for children under 18 years of age, as safety and efficacy have not been established. Elderly patients may have decreased liver, kidney, and heart functions, so they should start at a low dose and be administered with caution. Overdose may lead to severe hypotension, vasodilation, tachycardia, etc., and immediate medical attention should be sought for appropriate treatment. This medication should be stored away from direct sunlight and moisture, and kept out of reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. It is important to maintain a storage temperature between 1 and 30 degrees Celsius to safely preserve the medication's efficacy.
Light yellow round film-coated tablets
28 tablets (14 tablets/PTP x2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Pharma Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.